Hormonal
GLP-1 receptor agonists (GLP1RAs) and SGLT2 inhibitors should be used as first-line treatment in patients with Type 2 Diabetes and initial kidney disease, combined with Metformin.
If you have Type 2 Diabetes and early signs of kidney disease (like high blood pressure or protein in urine), ask your doctor about starting Metformin along with an SGLT2 inhibitor (like Jardiance or Farxiga). If more treatment is needed, a GLP-1 receptor agonist (like Ozempic or Trulicity) can be added. This combination is now recommended as the best way to protect your kidneys and heart.
recent American Diabetes Association (ADA)/ Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend combining Metformin with an SGLT2-i as first-line treatment in people with T2DM and initial kidney disease, with GLP1-RA being added in case of need of treatment intensification [33].
Why this rating
Based on recent ADA/KDIGO guidelines and multiple CVOTs showing renal benefits.
Source
Cardio‐renal‐metabolic disease in primary care setting
Mahmoud Ibrahim et al. · Diabetes/Metabolism Research and Reviews · 2023
DOI 10.1002/dmrr.3755
More from this paper
- SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with type 2 diabetes, regardless of baseline ejection fraction or diabetes status.Strong
- Intensive glycemic control (HbA1c <6.5%) in the first year after diagnosis of Type 2 Diabetes significantly reduces the 10-year risk of microvascular and macrovascular complications compared to higher HbA1c levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →